The abstract is read at the publisher; the summary is JClub's.
Modified-intensity RVD-lite in transplant-ineligible multiple myeloma achieved a median PFS of 42 months and median OS of 76 months after 72 months’ follow-up.
- Why it matters: Long-term outcomes for frail or older, transplant-ineligible patients remain a key gap, especially for regimens that balance efficacy with tolerability.
- What they did: In a multicenter investigator-initiated phase II trial of 50 patients, RVD-lite was given in 35-day cycles for 9 induction cycles then 6 consolidation cycles, with lenalidomide maintenance not mandated.
- The result: At best response ORR was 90% with 66% achieving ³VGPR; 5-year PFS was 40% and 5-year OS was 63%, and ECOG performance status 2 was linked to inferior PFS and OS.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.